(RTTNews) - Crinetics Pharmaceuticals Inc. (CRNX) has dosed the first patient in its Phase 2/3 trial of investigational drug Atumelnant for the treatment of classic congenital adrenal hyperplasia in ...
Based on Lim, S., Muralidharan, M., Esmail, S., and McKone, S., “Improving Analytical Flowing Material Balance Workflow Considering Formation Water Production ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results